Notice of NPPA to many pharma companies in the country

The National Pharmaceutical Pricing Authority (NPPA) said that in India, all pharma companies are coming out in the market by fixing the regulatory approval without fixing prices. There are 200 medicines in the NPPA list, which include Fixed Dosage Combination (FDC) and large pharmaceutical companies. NPPA has said in the show cause notice to the pharma companies, it is not clear whether these formulations have been approved by the Central Drug Standards Control Organization (CDSCO) and whether these drugs are logical as a combination drug. The companies have been given time till June 15, after which action will be taken.
On the other hand, DG Shah, general secretary of the Indian Association of Indian Pharmaceuticals Alliance issued a statement saying that the organization will wait for the names of the companies which the regulator has said. In NPPA’s notice, pharmaceutical companies have been charged that the formulation has been modified, which comes under the control of the price control, in which the strength of the drug or the dosage changes. NPPA can decide the price of any medicine, which falls under Schedule-1. NPPA can monitor prices of any non-schedule drug.
NPPA can also ensure that the prices of these drugs do not rise by more than 10 percent annually. If you look at this report printed in Business Standard, then the Drug Price Regulator has asked the companies to give detailed details of the batching production and sale, which includes maximum retail price (MRP). In the notice, state drug regulators have been asked to monitor the unauthorized medicines sold in the market. The NPPA has adopted a tough attitude towards pharmaceutical companies, who are allegedly violating the prescribed price limit. In February, NPPA had issued notice to the 634 drugs for excessive value. Even this time NPPA found that their number is high, so only the show cause notice has been sent to them. NPPA is also monitoring the prices of medical devices such as heart valves, Orthopedic implants and others. India’s drug regulator has asked to keep its side soon after cleansing of 65 domestic and foreign companies seeking to sell diabetes and antibiotics without approval. These include Abbott Laboratories, Sanofi, Novartis, Sun Pharmaceutical Industries and Lupine.

Source: Medicare News